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OBJECTIVES The effect of vardenafil, a potent and highly selective phosphodiesterase-5 (PDE5) inhibitor,
on symptom-limited exercise time, time to first awareness of angina, and time to ischemic
threshold (ST-segment depression 1 mm from baseline) during exercise tolerance testing
(ETT) was examined in patients with stable coronary artery disease (CAD).
BACKGROUND Erectile dysfunction (ED) is common among men with CAD. PDE5 inhibition is
increasingly the preferred treatment option for ED. However, the effect of PDE5 inhibition
on exercise-induced ischemia in CAD patients has received limited prospective evaluation.
METHODS In this double-blind, crossover, single-dose multicenter study, 41 men with reproducible stable
exertional angina due to ischemic CAD received vardenafil 10 mg or placebo, followed by ETT
(5 to 10 metabolic equivalents [METS], Bruce protocol) 1 h postdose. Sublingual nitrate use was
prohibited for 24 h pre- and postexercise study days. End points included symptom-limited
treadmill exercise time, time to first awareness of angina, time to ischemic threshold, and safety.
RESULTS Relative to placebo, vardenafil 10 mg did not alter exercise treadmill time (427  105 s vs.
433  109 s, p  0.39), or time to first awareness of angina (292  110 s vs. 291  123 s,
p 0.59), but significantly prolonged time to ischemic threshold (334 108 s vs. 381 108,
p  0.0004). At peak exercise, vardenafil 10 mg did not alter blood pressure, heart rate, or
rate-pressure product relative to placebo. The most common adverse events (facial flushing
and headache) were of mild or moderate intensity, and short-lived.
CONCLUSIONS Vardenafil 10 mg did not impair the ability of patients with stable CAD to exercise at levels
equivalent or greater than that attained during sexual intercourse (average of 2.5 to 3.3
METS). (J Am Coll Cardiol 2002;40:2006–12i) © 2002 by the American College of
Cardiology Foundation
Erectile dysfunction (ED) is often observed in men with
cardiovascular disease, and some investigators have sug-
gested that ED may serve as a predictor for this condition
(1). In epidemiologic studies, hypertension, ischemic heart
disease, and peripheral vascular disease are frequently asso-
ciated with ED (2,3). The association between ED and
coronary artery disease (CAD) is supported by results from
several studies that correlate CAD with difficulty in achiev-
ing erections (4–9). In some, the onset of ED predated the
symptoms and diagnosis of CAD (9).
Sildenafil was the first oral phosphodiesterase-5 (PDE5)
inhibitor for the treatment of men with ED. However,
significant concerns about the possible systemic hemody-
namic effects of this drug, particularly in combination with
other vasoactive cardiovascular medications, prompted the
American College of Cardiology/American Heart Associa-
tion (ACC/AHA) to provide guidelines regarding its use,
especially in patients with ischemic heart disease (10).
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Vardenafil is a highly selective PDE5 inhibitor (11,12).
The efficacy and safety of vardenafil (dosed at 5, 10, or 20
mg) has been demonstrated in Phase II (13) and Phase III
trials involving men with ED of various etiologies (14),
including type 2 diabetes mellitus (15) and postprostatec-
tomy (16). The present study examines the effect of vard-
enafil on symptom-limited treadmill exercise time, first
awareness of development of angina, time to ischemic
threshold (time to ST-segment depression 1 mm change
from baseline) during treadmill exercise using the Bruce
protocol, and effects on heart rate and blood pressure at rest
and during exercise in patients with stable CAD.
METHODS
Study design. The trial was performed using a random-
ized, double-blind, placebo-controlled, crossover, single-
dose multicenter study design (Fig. 1). Following a placebo
run-in and screening, patients with reproducible exertional
angina or angina-equivalent performed an exercise tolerance
test (ETT) after administration of 10 mg vardenafil or
placebo. Following a 5- to 21-day washout period, patients
were crossed over to the alternate treatment. The study
protocol and amendments were prepared in accordance with
the Declaration of Helsinki and with the Investigational
New Drug and Bioresearch Regulations of the United
States Food and Drug Administration. The study protocol
and amendments were approved by the Institutional Review
Board/Independent Ethics Committee at each investigator’s
institution, and written informed consent was obtained
from all patients.
Objectives. The primary objective of this study was to
determine the influence of vardenafil compared to placebo
on total exercise time in patients with exertional angina of
moderate severity and/or cardiac ischemia during exercise
(termination of exercise due to angina or appearance of
ST-segment depression 1 mm change from baseline on
electrocardiogram [ECG]) between 3 to 10 min of exercise.
Secondary measures included the time to first awareness of
angina, and time to ischemic threshold (time to onset of
ST-segment depression change from baseline of 1 mm).
Patient selection. Men between 40 and 80 years of age
with stable CAD were eligible for inclusion in the study.
Erectile dysfunction was not a specified inclusion or exclu-
sion criteria for study eligibility. Subjects were excluded if
they had evidence of major organ system failure that might
impair their ability to complete the study; body mass index
35; vasospastic or unstable angina; resting 12-lead ST-
segment depression 1.0 mm; clinically relevant chrono-
tropic incompetence; symptomatic postural hypotension
(supine systolic 90 mm Hg); sinus bradycardia (45
beats/min) or resting heart rate 110 beats/min; significant
exercise-induced hypotension (in the investigator’s opinion
from prior history); ST-segment elevations on treadmill
exercise testing in non–Q-wave leads; New York Heart
Abbreviations and Acronyms
CAD  coronary artery disease
DBP  diastolic blood pressure
ECG  electrocardiogram
ED  erectile dysfunction
ETT  exercise tolerance test
METS  metabolic equivalents
MI  myocardial infarction
PDE5  phosphodiesterase-5
SBP  systolic blood pressure
Figure 1. Diagramatic representation of study design. ETT  exercise tolerance test.
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Association functional class III or IV congestive heart
failure; significant pulmonary disease; significant cardiac
rhythm disorder; severe aortic stenosis; left bundle branch
block; significant left main disease (50% occlusion) that
had not been surgically corrected; significant peripheral
vascular disease; malignancy other than squamous or basal
cell carcinoma in situ; acute or significant psychiatric or
mental illness; epilepsy or adult seizure disorders; hypersen-
sitivity to PDE5 inhibitors; or allergy to 2 drug classes.
Also excluded were patients unable to discontinue sub-
lingual nitrates 24 h before and after an ETT and those
unable to discontinue slow-release and or long-acting ni-
trates one week before visit 1 and throughout the remainder
of the study. Concurrent use of corticosteroids, azole anti-
mycotics (except fluconazole), macrolides (except azithro-
mycin), nefazodone, rifampin, androgens, immunosuppres-
sants, and any drug known to interfere with cytochrome
P-450 was grounds for exclusion as was concurrent sildenafil
use within five days of any ETT visit, or consumption of
grapefruit juice or products containing grapefruit juice
within 24 h before each dosing. Aspartate aminotransferase,
alanine aminotransferase, or creatine kinase 3 times the
upper limit of normal, hematocrit 32% at screening and
optional follow-up, serum creatinine 2.0 mg/dl at screen-
ing, and any other laboratory abnormalities judged to be
clinically significant were grounds for exclusion, in addition
to a history of drug or alcohol abuse, or blood donation or
investigational drug use within 30 days of visit 1. Patients
were screened by complete physical examination, medical
history, chest X-ray, ECG, and laboratory tests up to three
weeks before study commencement. Patients were required
to discontinue slow-release and long-acting nitrates one
week before visit 1 and could not resume taking them until
after study completion. Patients must have been withdrawn
from sublingual nitrates 24 h before ETT and could not
resume taking them for 24 h after completing the test.
Patients taking beta-blockers, diltiazem, and/or verapamil
postponed their dose of these medications on the mornings
of each ETT until after it was completed. The continued
use of aspirin, dihydropyridine calcium channel blockers,
ACE inhibitors, and diuretics was allowed.
Study procedures. EXERCISE TOLERANCE TESTING. The
ETTs were conducted 1 h after study drug administration in
the morning, using the standard Bruce protocol. Blood
pressure and heart rate were recorded before ETTs (supine
after 5 min, sitting after 2 min, and standing after 2 min at
baseline), at the last minute of exercise during each Bruce
Stage (standing), when and if angina occurred, at termina-
tion of exercise, and every 2 min postexercise (sitting) until
patients were stable. At completion, patients rated their
perceived degree of exertion on a modified Borg scale (0 to
10) (17). The ECGs were monitored continuously during
the test by the investigator through at least three leads (two
chest and one limb lead). A 12-lead ECG was recorded
every minute during the test by the investigator. The ECGs
were examined continuously during the test for ST-segment
changes. If present, the time to ST-segment depression 1
mm change from baseline, the maximum ST-segment
depression from baseline, and the time to resolution of
significant ST-segment change were all recorded.
PATIENT QUALIFICATION. Patients were qualified for the
study based on the results of two ETTs separated by 5 to 21
days (visits 1 and 2). At both visits, patients had to be able
to exercise for 3 min using a standard Bruce ETT
protocol. They must also have terminated the ETT within
10 min because of symptoms of angina pectoris or angina
equivalents (intensity of at least 7 on a scale of 1 to 10)
and/or significant ST-segment depression, defined as a
1-mm horizontal or downsloping change from baseline or
2-mm slowly upsloping change from baseline. In addi-
tion, symptom-limited total exercise time on treadmill at
visits 1 and 2 could not differ from each other by more than
15%. If the first two ETTs did not meet this criterion,
patients were allowed to return one week later for a third
qualifying test. Results of this test were required to be
within 15% of those for the second test in order for the
patient to enter double-blind treatment. If the patient
terminated exercise because of anginal equivalent of short-
ness of breath, there must have been additional evidence of
myocardial ischemia (i.e., positive prior imaging study with
similar symptoms).
During the double-blind phase of the study, patients
meeting the above reproducibility criteria received either
vardenafil 10 mg orally or placebo 1 h before symptom-
limited ETT. Each treatment was administered after an
overnight fast. After a 5- to 21-day washout period, patients
were crossed over to the alternate treatment.
Pharmacokinetics. Blood samples were drawn 90 min
after dosing for determination of plasma vardenafil concen-
trations. The vardenafil assay used reverse-phase high per-
formance liquid chromatography with mass spectroscopy/
mass spectroscopy detection (18). Calibration curves ranged
from 0.5 to 50 g/l for vardenafil. Precision ranged from
2.06% to 5.87%, and accuracy ranged from 89.1% to
102.8%.
Safety analysis. All patients who received vardenafil were
evaluated for safety. Observations pertinent to safety in-
cluded results from clinical laboratory tests, physical exam-
inations, vital signs, ECGs, and adverse events.
Data analysis. The natural logarithm of the time to termi-
nation of exercise was analyzed using analysis of variance
with terms for sequence, patient within sequence, period,
and treatment. Because the study population was small,
logarithmic transformation of the data was performed con-
sistent with standard biometric protocols and the prospec-
tively designed statistical plan. A one-sided test procedure
with noninferiority limit of 0.85 and significance level of 5%
was used to determine noninferiority. A one-sided test
procedure was chosen because the measure of interest was
the potential for vardenafil to impair the ability of patients
to endure exercise. The influence of vardenafil versus pla-
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cebo was considered to be noninferior if least square (LS)
mean differences (LS, means corrected for sequence, patient
within sequence, period, and treatment) were 15%. Ret-
rospective analysis examined the influence of vardenafil in
the subpopulation of patients who exhibited both angina
and ST-segment changes1 mm from baseline. Retrospec-
tive analysis was also performed to determine the influence
of vardenafil, relative to placebo, on heart rate, systolic and
diastolic pressures, and the heart rate-pressure product
measured at baseline (1 h postdose) and at peak exercise.
Frequencies of adverse events, summary statistics for vital
signs and ECGs, and changes from baseline in vital signs
and ECG were determined for each treatment period.
RESULTS
Study cohort. A total of 53 patients were screened, and 41
were randomized to double-blind treatment. Of the 12
patients not randomized, 5 failed to meet inclusion criteria
(ETT requirements), 3 failed to adhere to the protocol
screening timeline, and 1 each violated protocols due to
concomitant medication, laboratory abnormality, work-
schedule conflict, or a positive test for illicit drug use. All 41
randomized patients completed the study. Of these, 39
patients were considered valid per protocol. One patient was
excluded from analysis due to disallowed concomitant med-
ication usage (erythromycin). Another patient was excluded
from analysis as a consequence of inadvertently exceeding
the maximal treadmill time. Most of the patients complet-
ing double-blind treatment had 1 cardiovascular risk
factor and were taking one or more cardiovascular medica-
tions (Table 1). In 17% of patients, a diagnosis of ED was
present. Overall, the patients who entered double-blind
treatment were representative of a population with well-
controlled cardiac disease.
Effects of treatment on exercise tolerance testing.
Relative to placebo, vardenafil 10 mg did not significantly
alter mean total exercise treadmill time (427  105 s for
placebo vs. 433  109 s for vardenafil, mean  SD, p 
0.394) or time to first awareness of angina pectoris (292 
110 s for placebo vs. 291  123 s for vardenafil, p  0.594;
Fig. 2). However, vardenafil significantly prolonged the
time to ST-segment depression 1 mm change from
baseline (334  108 s for placebo vs. 381  108 s for
vardenafil, p  0.0004; Fig. 2).
One patient was excluded from the analysis after exceed-
ing the defined time interval for total exercise duration in
the qualifying ETT (10 min) due to staff error. Following
double-blind treatment with vardenafil or placebo, the total
exercise duration was 12 min 7 s (727 s) and 11 min 45 s
(705 s), respectively. This represented a 3% improvement
under active drug conditions, consistent with the overall
mean change. The time to first awareness of angina im-
proved by 40 s without evidence of ST-segment depres-
sion 1 mm.
Similar results were obtained in a subgroup of patients
(n  27) who exhibited angina and ST-segment depression
1.0 mm (Table 2). Vardenafil 10 mg did not significantly
alter mean exercise treadmill time, or time to first awareness
of angina pectoris, but significantly prolonged the time to
ST-segment depression 1 mm change from baseline (331
 104 s for placebo vs. 377  109 s for vardenafil vs. p 
0.002). Uncorrected mean data demonstrated similar find-
ings compared to logarithmically transformed data de-
scribed above.
Pharmacokinetics. The concentration of vardenafil in
plasma from blood samples taken approximately 90 min
after dosing was 7.9  5.1 ng/ml (mean  SD; range
1.2–23.0 ng/ml), a concentration near maximal plasma
concentration of vardenafil observed after a 10-mg dose in
previous pharmacokinetic studies (18,19).
Safety. There were no treatment-emergent, clinically rele-
vant changes in blood pressure (BP), heart rate (HR),
respiration rate, or body temperature. Changes in BP, HR,
and rate-pressure product that occurred during exercise
testing were consistent with exertion levels achieved during
treadmill exercise. At baseline (1 h postdose), resting stand-
ing systolic blood pressure (SBP) and diastolic blood pres-
sure (DBP) in the vardenafil 10-mg group was 6 mm Hg
and 5 mm Hg less (p  0.05) compared to placebo. The
resting standing HR was also higher in the vardenafil 10-mg
group compared to placebo (3 beats/min, p 0.05), with no
clinically relevant change in rate-pressure product. At peak
exercise, both SBP and DBP were lower following vard-
enafil 10 mg by 8 and 7 mm Hg, respectively, compared to
Table 1. Demographic and Clinical Characteristics of Patients
Who Entered the Double-Blind Treatment Phase of the Study
Total
(n  41)
Race
Caucasian 30 (73%)
Black 10 (24%)
Hispanic 1 (2%)
Age (yrs), mean 61.9
BMI (kg/m2) 28.4
Cardiovascular risk factors
Hyperlipidemia 32 (78%)
Hypertension 25 (61%)
Diabetes 6 (14%)
MI 25 (61%)
Revascularization 19 (46%)
ED/impotence 7 (17%)
Concomitant medications
Nitrate use 20 (49%)*
Aspirin 22 (54%)
Lipid-lowering agent 31 (76%)
Beta-blocker 30 (73%)
ACE inhibitor 13 (32%)
Calcium channel blocker 7 (17%)
Diuretic 5 (12%)
Other antihypertensive 2 (5%)
*Sublingual nitrate use was prohibited for 24 h pre- and post-study. Long-acting
nitrates were discontinued one week prior to start and during the entire study.
ACE  angiotensin-converting enzyme; BMI  body mass index; ED  erectile
dysfunction; MI  myocardial infarction.
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placebo (p  0.05). There was no difference in HR
following treatment with vardenafil 10 mg. When corrected
for preexercise resting values, no significant differences
existed in HR or BP changes with exercise with vardenafil
10 mg relative to placebo. At peak exercise, indirect measure
of myocardial oxygen demand (rate-pressure product) was
not altered by vardenafil 10 mg relative to placebo (Table 3).
All exercise-induced ECG changes noted during testing
were consistent with each patient’s underlying CAD.
Overall, vardenafil was well tolerated; 24% (n  10) of
the patients experienced adverse events during treatment
with vardenafil versus 2% (n  1) for placebo. All adverse
events are consistent with those that might be expected to
occur as a result of vasodilation with PDE5 inhibition
(Table 4). Adverse events were typically mild in intensity
and were self-limiting. No treatment-emergent, clinically
significant abnormalities were identified on physical exam-
ination, ECG, or laboratory measurements. No patient was
discontinued prematurely because of adverse events. One
serious adverse event, sepsis associated with an E. coli
infection, was reported four days after vardenafil treatment.
The patient was hospitalized, treated with antibiotics, and
made a complete recovery. No deaths occurred during this
study.
DISCUSSION
The results of this study in symptomatic patients with stable
CAD who tolerated at least 3 min on ETT using the Bruce
protocol showed that, relative to placebo, vardenafil did not
alter total treadmill exercise time or time to the onset of
angina. Interestingly, vardenafil significantly increased isch-
emic threshold (as occurred by ST-segment depression)
during exercise by approximately 15% relative to placebo.
Furthermore, there were no untoward hemodynamic effects
of exercise as changes in HR, BP, and rate-pressure product
were similar in both placebo- and vardenafil-treated pa-
tients. These results support the conclusion that adminis-
tration of vardenafil 10 mg to patients with stable symp-
tomatic CAD does not exacerbate an ischemic response to
exercise relative to placebo at an exertional level of approx-
imately 5 to 10 metabolic equivalents (METS). This level is
similar to or greater than energy levels typically required to
complete sexual intercourse (average of 2.5 to 3.3 METS,
range of 2 to 5.4 METS) (20).
This is the first study to evaluate the effects of vardenafil
during exercise in patients with stable CAD with or without
angina. In a recent study, single-dose sildenafil did not
adversely influence total exercise duration in patients with
Figure 2. Effects of vardenafil (V) 10 mg and placebo (PLA) on exercise parameters. Open bars  placebo group; solid bars  vardenafil group. LS 
least-square.
Table 2. Effects of Vardenafil 10 mg and Placebo on Exercise Parameters in Patients With
Angina and 1 mm ST-Segment Depression
Parameter* Placebo Vardenafil (10 mg)
Ratio of LS Means
(Vardenafil/Placebo)
p
Value
Total treadmill
exercise time
428  101 (n  27) 433  110 (n  27) 1.004 0.842
Total time to angina
pectoris (first awareness)
290  103 (n  27) 292  125 (n  27) 0.972 0.584
Total time to
ST-segment depression
1 mm  from
baseline
331  104 (n  27) 377  109 (n  27) 1.146 0.002
Least-square (LS) mean data have been corrected for sequence, patient within sequence, period, and treatment.
*Mean  SD.
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exercise-induced angina and myocardial ischemia (21). In
that study, total exercise duration increased, but ischemic
threshold did not change after sildenafil compared to
placebo. Similar results were reported in patients with
known or probable CAD and ED, where sildenafil altered
resting, but not exercise-induced cardiovascular dynamics
following supine bicycle exercise (22). Interestingly, the latter
study only included patients with ED, compared to the present
study, in which 17% of patients volunteered their ED history.
Collectively, these findings reinforce the concept that the
negligible systemic hemodynamic effect of PDE-5 inhibition
in patients with chronic stable angina during exercise is largely
unrelated to the specific effects of PDE5 inhibition on regional
(corporal cavernosal) blood flow.
The finding that vardenafil increased ischemic threshold
implies that patients were able to undergo exercise for a
longer period without manifesting electrocardiographic ev-
idence of cardiac ischemia. An increase in ischemic thresh-
old has been reported with beta-blockers and with sublin-
gual nitrate regimens at dosages that do not produce
tolerance (23). These antianginal drugs, however, also
prolong exercise duration in patients with stable angina.
The majority of patients in the present study were taking
beta-blockers, although they did not take the beta-blocker
on the morning of the exercise test. Whether vardenafil will
exert anti-ischemic effects when given concomitantly with
beta-blockers before exercise needs further study. Collec-
tively, these findings are consistent with the view that PDE5
inhibitors do not adversely affect performance during stress
in patients with stable angina.
The cardiac stress associated with sexual activity has the
potential to increase the risk for cardiac events in patients
with CAD. However, for most patients, this risk is relatively
slight; the relative risk of a myocardial infarction (MI)
occurring within 2 h after sexual activity was 2.5 in patients
versus other times, and that the relative risks of triggering
onset of MI during this period among patients with a
history of prior angina or prior MI were 2.1 and 2.9,
respectively (24). Thus, sexual activity can trigger the onset
of MI, but the absolute risk is low.
Although sporadic reports of cardiac events in patients
taking sildenafil have been published (25,26), review of the
sildenafil experience supports its cardiovascular safety in a
wide range of patients, with no excess in the incidence rates
for death or MI among patients receiving sildenafil (27). In
addition, during the first 4.9 months of sildenafil use by
5,601 patients with ED, there was no evidence of increased
risk for MI or ischemic heart disease (28). Finally, sildenafil
caused no treatment-related cardiovascular adverse events
other than flushing in patients with both ED and cardio-
vascular disease (29). Based on these findings, the ACC/
AHA Expert Consensus Document recommended that
sildenafil be used with caution in certain men at risk for
cardiovascular events. More recently, the Princeton guide-
lines recommended that patients at low risk (including those
with mild stable angina) can be considered candidates for
sildenafil use, whereas patients at high risk be restricted
from its use (30). The ACC/AHA and Princeton recom-
mendations suggest there is a degree of cardiac risk associ-
Table 3. Effect of Vardenafil 10 mg on HR, Blood Pressure, and Rate-Pressure Product at Rest
and During Peak Exercise (n  41)
Variable Placebo
Vardenafil
10 mg
Mean Difference
(95% CI)
HR
Rest 70 (12) 73 (15) 3.44 (0.2 to 6.7)*
Peak exercise 129 (20) 131 (22) 1.83 (2.3 to 5.9)
Difference 59 (19) 57 (19) 1.61 (5.7 to 2.5)
SBP, mm Hg
Rest 136 (17) 129 (18) 6.34 (10.7 to 1.9)*
Peak exercise 165 (22) 156 (28) 7.51 (13.8 to 1.2)*
Difference 28 (19) 27 (21) 0.69 (6.2 to 4.8)
DBP, mm Hg
Rest 81 (11) 76 (10) 4.56 (7.3 to 1.8)*
Peak exercise 83 (19) 76 (22) 6.67 (9.2 to 4.1)*
Difference 2 (18) 1 (20) 1.56 (5.3 to 2.2)
Rate-pressure product (HR  SBP)
Rest 9,427 (1635) 9,468 (2198) 40.95 (517.1 to 599.0)
Peak exercise 21,273 (5019) 20,488 (5477) 706.08 (1761.9 to 349.7)
Difference 11,855 (4576) 11,024 (4962) 605.59 (1564.7 to 353.5)
Data are reported as mean (SD). *p  0.05; measurements taken in the standing position.
CI  confidence interval; DBP  diastolic blood pressure; HR  heart rate; SBP  systolic blood pressure.
Table 4. Adverse Events Reported During Treatment With
Vardenafil or Placebo
Adverse Event
Placebo
(n  41)
Vardenafil 10 mg
(n  41)
Any event 1 (2%) 10 (24%)
Vasodilation (facial flushing) 0 (0%) 5 (12%)
Headache 0 (0%) 3 (7%)
Tachycardia 0 (0%) 1 (2%)
Dizziness 1 (2%) 1 (2%)
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ated with sexual activity and that, before treating ED,
physicians should consider patients’ cardiovascular status
and/or the impact of their resuming sexual activity and
counsel them appropriately (20,30).
In the present study, patients did not take long-acting
nitrates throughout the study and they did not take sublin-
gual nitroglycerin 24 h prior to or after vardenafil adminis-
tration, consistent with the recommendations of the ACC/
AHA guidelines against concomitant use of nitrates and
sildenafil. Future studies need to be performed to develop
guidelines for the judicious use of anti-ischemic medica-
tions, including vasodilators, when patients with symptom-
limited angina may require additional support after PDE5
use in conjunction with sexual (or physical) activity.
In this limited study of 41 patients, vardenafil 10 mg was
well tolerated. Adverse events were either mild or moderate
and short-lived. The most common drug-related events
(facial flushing and headache) were consistent with the
vasodilating properties of the drug class. There were no
treatment-emergent, clinically significant changes on phys-
ical examination or in laboratory parameters. All changes in
the ECGs recorded during exercise testing were consistent
with patients’ underlying CAD. Larger studies are needed
to verify these findings.
Conclusions. In conclusion, vardenafil 10 mg did not
significantly alter patients’ response to exercise testing, and
delayed the onset of ST-segment changes relative to placebo
in 41 patients with stable CAD with or without exertional
angina pectoris. Thus, vardenafil 10 mg did not impair
CAD patients’ ability to exercise at a level considered
equivalent to or greater than sexual intercourse. When
considering vardenafil for the treatment of cardiac patients
exhibiting ED, physicians should consider the cardiovascu-
lar status of their patients as recommended by the ACC/
AHA guidelines (20).
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